[1]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153-155.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Journal of Medical Information,2019,32(09):153-155.[doi:10.3969/j.issn.1006-1959.2019.09.051]
点击复制

阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年09期
页码:
153-155
栏目:
药物与临床
出版日期:
2019-05-01

文章信息/Info

Title:
Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia
文章编号:
1006-1959（2019）09-0153-03
作者:
陈志萍
（保定裕东医院内科，河北 保定 071000）
Author(s):
CHEN Zhi-ping
(Department of Internal Medicine,Baoding Yudong Hospital,Baoding 071000,Hebei,China)
关键词:
阿托伐他汀; 低分子肝素; 短暂性脑缺血; 凝血功能
Keywords:
Atorvastatin; Low molecular weight heparin; Transient ischemic attack; Coagulation
分类号:
R743.31
DOI:
10.3969/j.issn.1006-1959.2019.09.051
文献标志码:
A
摘要:
目的 探讨阿托伐他汀联合低分子肝素治疗短暂性脑缺血的临床疗效及对患者凝血功能的影响。方法 选取2013年6月~2018年5月我院收治的短暂性脑缺血患者110例，随机分为观察组和对照组，各55例，对照组使用阿托伐他汀治疗，观察组患者在此基础上使用低分子肝素联合治疗。比较两组临床疗效、治疗前后凝血功能、血脂水平和不良反应情况。结果 观察组总有效率为95.12%，高于对照组的75.61%，差异有统计学意义（P＜0.05）；治疗后观察组凝血功能改善优于对照组，差异有统计学意义（P＜0.05）；治疗后，观察组HDL-C水平高于对照组[（1.62±0.11）mmol/L vs（1.31±0.23）mmol/L]，差异有统计学意义（P＜0.05）；TC[（5.09±0.43）mmol/L vs（5.92±0.61）mmol/L]、TG[（2.12±0.16）mmol/L vs（2.67±0.22）mmol/L]、LDL-C[（3.16±0.69）mmol/L vs（4.37±0.46）mmol/L]均低于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 阿托伐他汀联合低分子肝素治疗短暂性脑缺血疗效显著，可明显改善患者凝血功能和血脂水平，且不增加不良反应，安全性较好。
Abstract:
Objective To investigate the clinical efficacy of atorvastatin combined with low molecular weight heparin in the treatment of transient cerebral ischemia and its effect on coagulation function.Methods A total of 110 patients with transient cerebral ischemia admitted to our hospital from June 2013 to May 2018 were randomly divided into observation group and control group, 55 cases in each group. The control group was treated with atorvastatin. The observation group was treated with This is based on the combination of low molecular weight heparin. The clinical efficacy, coagulation function, blood lipid level and adverse reactions before and after treatment were compared.Results The total effective rate was 95.12% in the observation group, which was higher than 75.61% in the control group,the difference was statistically significant (P<0.05). The improvement of coagulation function in the observation group was better than that in the control group, the difference was statistically significant (P<0.05). The level of HDL-C in the group was higher than that in the control group [(1.62±0.11) mmol/L vs (1.31±0.23) mmol/L], the difference was statistically significant (P<0.05); TC[(5.09±0.43) mmol/L vs(5.92±0.61)mmol/L], TG[(2.12±0.16)mmol/L vs(2.67±0.22)mmol/L],LDL-C [(3.16±0.69) mmol/L vs (4.37±0.46) mmol/L] was lower than the control group, the difference was statistically significant (P<0.05); the incidence of adverse reactions in the two groups was compared, the difference was not statistical Academic significance (P>0.05).Conclusion Atorvastatin combined with low molecular weight heparin is effective in the treatment of transient cerebral ischemia, which can significantly improve the blood coagulation function and blood lipid level of patients, without increasing adverse reactions and safety.

参考文献/References:

[1]徐东升,黄伟,陈炜,等.短暂性脑缺血发作患者血液标志物的检测及其临床意义[J].海南医学,2016,27(8):1219-1221．
[2]许坤,赵弘卿,冯金萍,等.低分子肝素钙和利伐沙班联合阿托伐他汀对急性肺栓塞患者相关指标的影响[J].中国药房,2017,28(21):2940-2943.
[3]短暂性脑缺血发作中国专家共识组.短暂性脑缺血发作的中国专家共识更新版（2011年）[J].中华内科杂志,2011,50(6):530-533.
[4]刘萍.低分子肝素钙及氯吡格雷对短暂性脑缺血发作短期疗效的对比[J].中国现代药物应用,2017,11(24):99-100.
[5]黄国敏,邓耀芳,黄丹丹,等.短暂性脑缺血发作患者行阿托伐他汀钙治疗对颈动脉粥样硬化斑块和血脂的影响[J].中国医药科学,2017,7(7):52-55.
[6]贾东影.浅析氯吡格雷联合低分子肝素钙治疗不稳定型心绞痛的临床效果及护理措施[J].中国现代药物应用,2017,11(3):143-145.
[7]郜静,赵鹏,刘敏肖.阿托伐他汀钙对TIA患者颈动脉粥样硬化斑块及脑血流指标的影响[J].海南医学院学报,2017,23(1):56-58.
[8]刘云.阿托伐他汀钙对短暂性脑缺血发作患者血脂及血液流变学指标影响[J].中国医学工程,2018,26(2):30-33.
[9]冯小春,冯波涛,李敏,等.低分子肝素和辛伐他汀联合氯吡格雷治疗不稳定型心绞痛的效果评估[J].中国医院药学杂志,2016,21(23):342-343.
[10]冯欣,黄晓飞,邹达良,等.依达拉奉联合低分子肝素钙治疗短暂性脑缺血发作用药效果初评[J].中外医学研究,2016,14(3):44-45.
[11]王明,邹乐乐,赵晓玲,等.肝素钠与低分子肝素钙治疗频发短暂性脑缺血发作的疗效对比[J].中国实用神经疾病杂志,2016,19(19):129-130.
[12]黄海涛.阿托伐他汀联合低分子肝素对 TIA 患者血液流变学的影响[J].中国实用神经疾病杂志,2015,18(24):29-31.

相似文献/References:

[1]何 丽.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比[J].医学信息,2022,35(11):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
　HE Li.Comparison of Three Statins in the Treatment of Elderly Patients with Atherosclerotic Acute Cerebral Infarction Combined with Hyperlipidemia[J].Journal of Medical Information,2022,35(09):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
[2]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Journal of Medical Information,2018,31(09):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[3]王润俊.阿托伐他汀改善蛛网膜下腔出血患者的预后分析[J].医学信息,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
　WANG Run-jun.Analysis of Atorvastatin Improves Prognosis in Patients with Subarachnoid Hemorrhage[J].Journal of Medical Information,2018,31(09):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
[4]袁 敏,周袁成.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对 血小板参数的影响[J].医学信息,2018,31(16):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
　YUAN Min,ZHOU Yuan-cheng.Effect of Atorvastatin Combined with Antiplatelet Drugs on Patients with Cerebral Thrombosis and its Influence on Platelet Parameters[J].Journal of Medical Information,2018,31(09):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
[5]钱朝庆,刘 淼,王家平,等.肾病综合征合并肾静脉血栓应用阿加曲班疗效评价[J].医学信息,2018,31(21):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
　QIAN Chao-qing,LIU Miao,WANG Jia-ping,et al.Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis[J].Journal of Medical Information,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
[6]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Journal of Medical Information,2019,32(09):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[7]沈有录,卢红涛,刘维军.阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响[J].医学信息,2019,32(06):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
　SHEN You-lu,LU Hong-tao,LIU Wei-jun.Effects of Atorvastatin and Rosuvastatin on Blood Lipids,Inflammatory Factors and Vascular Endothelial Function in Patients with High Altitude PCI[J].Journal of Medical Information,2019,32(09):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
[8]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Journal of Medical Information,2019,32(09):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[9]安志卫,刘 娜,薛芳芳.阿托伐他汀联合硫酸氢氯吡格雷治疗脑血栓的效果观察[J].医学信息,2019,32(17):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
　AN Zhi-wei,LIU Na,XUE Fang-fang.Effect of Atorvastatin Combined with Clopidogrel Hydrogen Sulfate on Cerebral Thrombosis[J].Journal of Medical Information,2019,32(09):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
[10]王晓芳.低分子肝素治疗COPD合并Ⅱ型呼吸衰竭的临床疗效[J].医学信息,2019,32(19):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
　WANG Xiao-fang.Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with Type II Respiratory Failure[J].Journal of Medical Information,2019,32(09):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]

更新日期/Last Update: 2019-05-01